ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 19.4% on Friday . The company traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.66 ($0.06). Approximately 16,775,158 shares traded hands during trading, a decline of 23% from the average daily volume of 21,727,129 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Stock Performance
The firm has a market cap of £20.11 million, a price-to-earnings ratio of -483.00 and a beta of 1.53. The stock’s fifty day moving average is GBX 2.39 and its two-hundred day moving average is GBX 1.93.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Industrial Products Stocks Investing
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Trading Stocks: RSI and Why it’s Useful
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
